Resources

Spark Therapeutics Generation Patient Services® is a program sponsored by Spark® Therapeutics for patients who have confirmed biallelic RPE65 gene mutations and may be candidates for treatment with LUXTURNA® (voretigene neparvovec-rzyl). Our goal is to provide your patients with personalized assistance throughout the patient’s journey.

The Spark Therapeutics Generation Patient Services support team will:

• Contact your patient within 1 to 2 business days after receiving the completed enrollment form
• Provide your patient with a caring support team, from confirmed diagnosis through postsurgery follow-up
• Ensure a single point of contact to help your patient navigate insurance coverage and get connected with financial assistance resources as needed
• Help to coordinate your patient’s ocular gene therapy treatment center visits
• Answer nonmedical questions your patient may have along the way

Because of legal requirements, not all services and resources are available to patients with government insurance. Enrollment in Spark Therapeutics Generation Patient Services is voluntary, and your patients are not required to enroll in order to receive treatment with LUXTURNA®.

Spark Therapeutics carefully designated ocular gene therapy treatment centers to support patient care. Each ocular gene therapy treatment center was determined based on specific criteria and is staffed with retinal specialists, nurses, and other healthcare professionals who have experience treating patients with inherited retinal diseases and have been educated on administering LUXTURNA.

Some of the criteria for ocular gene therapy treatment center selection include:

• Specialized scientific or clinical experience relevant to the administration of LUXTURNA
• The ability to properly receive, store, and prepare LUXTURNA
• A commitment to pharmacy and surgical education

If you decide that LUXTURNA is right for your patient, several factors will be considered in helping the patient determine their ocular gene therapy treatment center: your patient’s insurance coverage, in an effort to minimize out-of-pocket costs; your patient’s and the ocular gene therapy treatment center's schedules; and your and your patient's preference, among other considerations.

Yes, there are resources available to assist eligible patients with out-of-pocket costs. Eligibility for this support varies depending on certain criteria, including the type of insurance your patient has. Your Spark Therapeutics Generation Patient Services support team can help determine which resources are most appropriate and help your patient get connected.

Getting insurance approval for LUXTURNA may involve several steps. With your patient’s consent, Spark Therapeutics Generation Patient Services will contact your patient’s insurance company and request information on coverage and the approval process. Once a prescribing physician at an ocular gene therapy treatment center has determined that a patient is eligible for treatment with LUXTURNA, they will begin the request for treatment approval, known as prior authorization. The Spark Therapeutics Generation Patient Services team will be there to set expectations about the process and will inform your patient of any updates related to coverage and prior authorization along the way.

LUXTURNA is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation–associated retinal dystrophy. Patients must have viable retinal cells as determined by the treating physician(s).

To learn more about genetic testing, click here.

Participation in Spark Therapeutics Generation Patient Services is voluntary and is not required to get treatment with LUXTURNA. Your patient may choose to participate in all, some, or none of the services offered. Participating or deciding not to participate in these services will have no effect on their ability to get treatment or the nature of their treatment or care. Spark Therapeutics Generation Patient Services does not provide medical advice.

Once a completed enrollment form and patient authorization have been submitted, a member of the Spark Therapeutics Generation Patient Services team will reach out to your patient and schedule a consultation at an ocular gene therapy treatment center if they have confirmed biallelic RPE65 mutation–associated retinal dystrophy. A prescribing physician at the ocular gene therapy treatment center will determine if your patient has viable retinal cells and their eligibility for LUXTURNA. If it’s been determined that your patient is eligible, LUXTURNA will be ordered directly from the ocular gene therapy treatment center.

See below for a list of centers:
Alkek Eye Center, Baylor College of Medicine Jamail Specialty Care Center – Houston, TX
Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago, IL
Bascom Palmer Eye Institute, University of Miami Health System – Miami, FL
Boston Children’s Hospital – Boston, MA
Children’s Hospital of Philadelphia – Philadelphia, PA
Cincinnati Children’s Hospital – Cincinnati, OH
Dean McGee Eye Institute, University of Oklahoma - Oklahoma City, OK
Duke Eye Center, Duke University Health System - Durham, NC
Kellogg Eye Center, University of Michigan – Ann Arbor, MI
Massachusetts Eye and Ear – Boston, MA
Mayo Clinic - Rochester, MN
OHSU Casey Eye Institute – Portland, OR
Scheie Eye Institute Penn Presbyterian – Philadelphia, PA
UAB Callahan Eye – Birmingham, AL
UF Health Eye Center - Gainesville, FL
University of Iowa Hospitals and Clinics – Iowa City, IA
UPMC Eye Center - Pittsburgh, PA
University of Rochester Medical Center, Flaum Eye Institute – Rochester, NY
The Vision Center at Children’s Hospital Los Angeles – Los Angeles, CA